Allegra® Allergy Gears Up for Bike to Work Day Across the U.S.

BRIDGEWATER, N.J., May 11, 2017 /PRNewswire/ -- Sanofi Consumer Healthcare – the makers of Allegra^® Allergy – announced today that it is supporting Bike to Work Day events across the country as a way to help reduce air pollution and to get more people outdoors this spring. Allegra Allergy is an antihistamine that helps relieve allergy symptoms that can hold some people back from truly enjoying this season. Bike to Work Day is an annual observance on which people are encouraged to ride bicycles to work instead of driving, as a more environmentally friendly form of transportation. It takes place on May 19^th in most locations and on June 28^th in Denver, Colorado.

"Air pollution is one of the world's biggest global health problems, so a lot of people feel like there isn't anything they can do to make a difference but we want them to know that isn't the case. Every step counts – or in this case, every bike ride," said Holly Sisson, Senior Marketing Manager, Sanofi Consumer Healthcare. "That's why we are supporting Bike to Work Day this year – it's a great way for people to get involved, while also getting outside and enjoying the spring season."

A recent survey found that a majority of Americans (88%) are concerned about the impact of air pollution on their overall health. It also found that most Americans (90%) wish there was more they could do to get involved and help reduce air pollution. Participating in Bike to Work Day is a great place to start.

A variety of Bike to Work Day events are available across the country. Allegra will be supporting those taking place in Philadelphia, PA, Dayton, OH, Chattanooga, TN, Denver, CO and the Washington, D.C. metropolitan region. In certain locations, Allegra will also be working with local bike share programs to offer free 24-hour bike passes in recognition of Bike to Work Day. For additional information as these events near, follow Allegra on Twitter and Facebook.

About Allegra^® Allergy 
Allegra^® Allergy is an oral antihistamine that is available over-the-counter at full prescription strength to relieve indoor and outdoor allergy symptoms, including sneezing, runny nose, itchy watery eyes, and itchy nose or throat. It provides fast,** non-drowsy relief that starts in just one hour and stays strong for 24.*** Allegra can be used by adults and children 12 years of age and older. For more information, visit www.Allegra.com.

About Sanofi 
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

*This survey was conducted online using Toluna's QuickSurveys methodology between January 22, 2017 and January 24, 2017 among 1,256 adults (ages 18 and over) in the USA.  Respondents for Toluna QuickSurveys are selected from among those who have agreed to participate in Toluna surveys. Toluna's SmartSelect^TM methodology was used to promote sample representativeness. SmartSelect relies on statistical matching rather than probability sampling to select survey respondents, based on demographic, attitudinal and behavioral characteristics that match those of the target population. Figures for age, gender, region, race/ethnicity, education and income are also weighted to bring them into line with their actual proportions within the population. Because the sample is based on those who agreed to participate in Toluna surveys, no estimates of theoretical sampling error can be calculated.

**Starts working in one hour. Use only as directed.

*** Applies to adult formulations only.

Sanofi Forward-Looking Statements 
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

SOURCE Sanofi